國立虎尾科技大學 |

Evidence-biased Antidepressant Prescription = Overmedicalisation, Flawed Research, and Conflicts of Interest /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Evidence-biased Antidepressant Prescription/ by Michael P. Hengartner.
其他題名:	Overmedicalisation, Flawed Research, and Conflicts of Interest /
作者:	Hengartner, Michael P.
面頁冊數:	VII, 354 p.online resource. :
Contained By:	Springer Nature eBook
標題:	Public Health. -
電子資源:	https://doi.org/10.1007/978-3-030-82587-4
ISBN:	9783030825874

Evidence-biased Antidepressant Prescription = Overmedicalisation, Flawed Research, and Conflicts of Interest /
Hengartner, Michael P.

Evidence-biased Antidepressant PrescriptionOvermedicalisation, Flawed Research, and Conflicts of Interest /[electronic resource] :by Michael P. Hengartner. - 1st ed. 2022. - VII, 354 p.online resource.

1. Introduction: How did I get here? -- 2. Antidepressants in clinical practice -- 3. Medico-cultural context -- 4. Flaws in antidepressant research -- 5. Conflicts of interest in psychiatry -- 6. Solutions for reform.

This book addresses the over-prescribing of antidepressants in people with mostly mild and subthreshold depression. It outlines the steep increase in antidepressant prescription and critically examines the current scientific evidence on the efficacy and safety of antidepressants in depression. The book is not only concerned with the conflicting views as to whether antidepressants are useful or ineffective in various forms of depression, but also aims at detailing how flaws in the conduct and reporting of antidepressant trials have led to an overestimation of benefits and underestimation of harms. The transformation of the diagnostic concept of depression from a rare but serious disorder to an over-inclusive, highly prevalent but predominantly mild and self-limiting disorder is central to the books argument. It maintains that biological reductionism in psychiatry and pharmaceutical marketing reframed depression as a brain disorder, corroborating the overemphasis on drug treatment in both research and practice. Finally, the author goes on to explore how pharmaceutical companies have distorted the scientific literature on the efficacy and safety of antidepressants and how patient advocacy groups, leading academics, and medical organisations with pervasive financial ties to the industry helped to promote systematically biased benefit-harm evaluations, affecting public attitudes towards antidepressants as well as medical education, training, and practice. Michael P. Hengartner is a senior researcher and lecturer at the Zurich University of Applied Sciences, Switzerland. He has published over 130 peer-reviewed journal articles and four book chapters. He was an expert evaluator for the European Research Council and the World Health Organization and currently is a member of the Swiss School of Public Health, the German Society for Social Psychiatry, and the European Public Health Association.

ISBN: 9783030825874

Standard No.: 10.1007/978-3-030-82587-4doiSubjects--Topical Terms:

592982
Public Health.

LC Class. No.: RC466.8-467.97

Dewey Class. No.: 616.89

Evidence-biased Antidepressant Prescription = Overmedicalisation, Flawed Research, and Conflicts of Interest /
LDR:03558nam a22003975i 4500 001 1091642
003 DE-He213
005 20220127101212.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030825874 $9 978-3-030-82587-4
024 7 $a 10.1007/978-3-030-82587-4 $2 doi
035 $a 978-3-030-82587-4
050 4 $a RC466.8-467.97
072 7 $a MMJ $2 bicssc
072 7 $a PSY007000 $2 bisacsh
072 7 $a MKM $2 thema
082 0 4 $a 616.89 $2 23
100 1 $a Hengartner, Michael P. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1399247
245 1 0 $a Evidence-biased Antidepressant Prescription $h [electronic resource] : $b Overmedicalisation, Flawed Research, and Conflicts of Interest / $c by Michael P. Hengartner.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Palgrave Macmillan, $c 2022.
300 $a VII, 354 p. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a 1. Introduction: How did I get here? -- 2. Antidepressants in clinical practice -- 3. Medico-cultural context -- 4. Flaws in antidepressant research -- 5. Conflicts of interest in psychiatry -- 6. Solutions for reform.
520 $a This book addresses the over-prescribing of antidepressants in people with mostly mild and subthreshold depression. It outlines the steep increase in antidepressant prescription and critically examines the current scientific evidence on the efficacy and safety of antidepressants in depression. The book is not only concerned with the conflicting views as to whether antidepressants are useful or ineffective in various forms of depression, but also aims at detailing how flaws in the conduct and reporting of antidepressant trials have led to an overestimation of benefits and underestimation of harms. The transformation of the diagnostic concept of depression from a rare but serious disorder to an over-inclusive, highly prevalent but predominantly mild and self-limiting disorder is central to the books argument. It maintains that biological reductionism in psychiatry and pharmaceutical marketing reframed depression as a brain disorder, corroborating the overemphasis on drug treatment in both research and practice. Finally, the author goes on to explore how pharmaceutical companies have distorted the scientific literature on the efficacy and safety of antidepressants and how patient advocacy groups, leading academics, and medical organisations with pervasive financial ties to the industry helped to promote systematically biased benefit-harm evaluations, affecting public attitudes towards antidepressants as well as medical education, training, and practice. Michael P. Hengartner is a senior researcher and lecturer at the Zurich University of Applied Sciences, Switzerland. He has published over 130 peer-reviewed journal articles and four book chapters. He was an expert evaluator for the European Research Council and the World Health Organization and currently is a member of the Swiss School of Public Health, the German Society for Social Psychiatry, and the European Public Health Association.
650 2 4 $a Public Health. $3 592982
650 2 4 $a Psychopathology. $3 647313
650 2 4 $a Medical Anthropology. $3 1116087
650 2 4 $a Medical Sociology. $3 1105129
650 1 4 $a Clinical Psychology. $3 668193
650 0 $a Public health. $3 560998
650 0 $a Psychology, Pathological. $3 554802
650 0 $a Medical anthropology. $3 803576
650 0 $a Social medicine. $3 558786
650 0 $a Psychiatry. $3 585488
650 0 $a Clinical psychology. $3 649607
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030825867
776 0 8 $i Printed edition: $z 9783030825881
776 0 8 $i Printed edition: $z 9783030825898
856 4 0 $u https://doi.org/10.1007/978-3-030-82587-4
912 $a ZDB-2-BSP
912 $a ZDB-2-SXBP
950 $a Behavioral Science and Psychology (SpringerNature-41168)
950 $a Behavioral Science and Psychology (R0) (SpringerNature-43718)